New concepts in the management of adverse drug reactions

Allergy and Asthma Proceedings

Volumn 28, Issue 5, 2007, Pages 517-524

  Bahna, Sami L ^a   Khalili, Barzin ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Drug allergy; Drug cross reactivity; Drug hypersensitivity; Immunoglobulin therapy; Infliximab; Nsaids; Pancreatic enzyme; Stevens Johnson syndrome; Sulfonamides; Toxic epidermal necrolysis

Indexed keywords

EID: 36649009323     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap2007.28.3030     Document Type: Review

References (55)

1. Paquet P, Pierard GE, and Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 136:205-216, 2005.
2. Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: A review of the literature. Ann Allergy Asthma Immunol 94:419-436, 2005.
3. Schōpf E, Stūhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: An epidemiologic study from West Germany. Arch Dermatol 127:839-842, 1991.
4. Leehutaphong V, Sivayathon A, Suthipinittharm P, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol 32:428-431, 1993.
5. Roujeau JC, and Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 331:1272-1285, 1994.
6. Sheretz EF, Jegasothy BV, and Lazarus GS. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. J Am Acad Dermatol 12:178-181, 1985.
7. Patterson R, Miller M, Kaplan M, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: Experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 73:27-34, 1994.
8. Kim PS, Goldfarb IW, Gaisford JC, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: A pathophysiologic review with recommendations for a treatment protocol. J Burn Care Rehabil 4:91-100, 1983.
9. Halebian PH, Corder VJ, Madden MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed with corticosteroids. Ann Surg 204:503-512, 1986.
10. Khalili B, and Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol 97:272-281, 2006.
11. Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 134:710-714, 1996.
12. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490-493, 1998.
13. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson Syndrome are induced by soluble Fas ligand. Am J Pathol 162:1515-1520, 2003.
14. Werhrli P, Viard I, Bullani R, et al. Death receptors in cutaneous biology and disease. J Invest Dermatol 115:141-148, 2000.
15. Bachot N, and Roujeau JC. Intravenous immunoglobulins in the treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol 3:269-274, 2003.
16. Trent JT, Kirsner RS, Romanelli P, et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami experience. Arch Dermatol 139:39-43, 2003.
17. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149-153, 2000.
18. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139:26-32, 2003.
19. Morici MV, Galen WK, Shetty AK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson Syndrome. J Rheumatol 27:2494-2497, 2000.
20. Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 47:548-552, 2002.
21. Bachot N, Revuz J, and Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: A prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139:33-36, 2003.
22. Shortt R, Gomez M, Mittman N, et al. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 25:246-255, 2004.
23. Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: Does immunoglobulin make a difference? J Burn Care Rehabil 25:81-88, 2004.
24. Knowles S, Shapiro L, and Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Drug Safety 24:239-247, 2001.
25. Harle DG, Baldo BA, and Wells JV. Drugs as allergens: Detection and combining site specificities of IgE antibodies to sulfamethoxazole. Mol Immunol 25:1347-1354, 1988.
26. Brackett CC, Singh H, and Block JH. Liklihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. Pharmacotherapy 24:856-870, 2004.
27. Cribb A, Lee B, Trepanier L, et al. Adverse reactions to sulfonamide and sulfonamide-trimethoprim antimicrobials: Clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 15:9-50, 1996.
28. Johnson KK, Green DL, Rife JP, et al. Sulfonamide cross-reactivity: Fact or fiction? Ann Pharmacother 39:290-301, 2005.
29. Strom B, Schinnar R, Apter A, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 349:1628-1635, 2003.
30. Stevenson D. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 24:491-505, 2004.
31. Vigano T, Habib A, Hernandez A, et al. Cyclooxygenase-2 and synthesis of PGE2 in human bronchial smooth-muscle cells. Am J Respir Crit Care Med 155:864-868, 1997.
32. Szczeklik A, and Sanak M. Molecular mechanisms in aspirin-induced asthma. ACI Int 12:171-176, 2000.
33. Celik G, Bavbek S, Misirhgil Z, et al. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E(2) on this release from peripheral blood leucocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 31:1615-1622, 2001.
34. Bavbek S, Celik G, Ozer F, et al. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: Comparison of nimesulide, meloxicam, and rofecoxib. J Asthma 41:67-75, 2004.
35. Senna G, Bilo MB, Antonicelli L, et al. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib, and rofecoxib in NSAID-sensitive patients. Allergy Immunol 36:215-218, 2004.
36. Kowalski ML. Aspirin-sensitive rhinosinusitis/asthma syndrome- pathophysiology and management. ACI Int 8:49-56, 1996.
37. Woessner K, Simon R, and Stevenson D. The safety of celecoxib in aspirin exacerbated respiratory disease. Arthritis Rheum 46: 2201-2206, 2002.
38. Gyllfors P, Bochenek G, Overholt J, et al. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgesic drug celecoxib. J Allergy Clin Immunol 111:1116-1121, 2003.
39. Stevenson D, and Simon R. Lack of cross-reactivity between rofecoxib and aspirin in aspirin sensitive asthmatic patients. J Allergy Clin Immunol 108:47-51, 2001.
40. Woessner KM, Simon RA, and Stevenson DD. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 93:339-344, 2004.
41. El Miedany Y, Youssef S, Ahmed I, et al. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 97:105-109, 2006.
42. Zembowicz A, Mastalerz L, Setkowicz M, et al. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to non-steroidal anti-inflammatory drugs. Arch Dermatol 139:1577-1582, 2003.
43. Quiralte J, Delgado J, Saenz de San Pedro B, et al. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 93:360-364, 2004.
44. Nettis E, Colanardi M, Ferrannini A, et al. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 94:29-33, 2005.
45. Sanchez-Borges M, Caballero-Fonseca F, and Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 94:34-38, 2005.
46. Celik G, Erkekol FO, Bavbek S, et al. Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance. Ann Allergy Asthma Immunol 95:33-37, 2005.
47. Bresalier RS, Sandler RS, Quan HQ, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102, 2005.
48. Chamarthy LM, Reinstein LJ, Schnapf B, et al. Desensitization to pancreatic enzyme intolerance in a child with cystic fibrosis. Pediatrics 102:134-135, 1998 (Abs). (Full paper available online at www.pediatrics.org/cgi/ content/full/102/1/e13.)
49. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol 98:1315-1324, 2003.
50. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT 1 randomised trial. Lancet 359:1541-1549, 2002.
51. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601-608, 2003.
52. Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 38:502-508, 2004.
53. Puchner TC, Kugathasan S, Kelly KJ, et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 7:34-37, 2001.
54. Lelong J, Duburque C, Fournier C, et al. Desensitization to infliximab in patients with Crohn's disease. Rev Mal Respir 22:239-246, 2005.
55. Bangash S, Kaufman D, Moissidis I, et al. Infliximab desensitization. J Allergy Clin Immunol 115:S180, 2005 (Abs).